Opendata, web and dolomites

Rosalind SIGNED

Scale-up for Next Generation Enzymatic DNA Synthesis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Rosalind" data sheet

The following table provides information about the project.

Coordinator
DNA SCRIPT SAS 

Organization address
address: 67 AVENUE DE FONTAINEBLEAU, IMMEUBLE OKABE
city: LE KREMLIN-BICETRE
postcode: 94270
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://dnascript.co/project-rosalind
 Total cost 3˙568˙437 €
 EC max contribution 2˙497˙906 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNA SCRIPT SAS FR (LE KREMLIN-BICETRE) coordinator 2˙497˙906.00

Map

 Project objective

DNA Script is a biotech company founded in 2014, developing an enzymatic process for DNA synthesis, i.e. manufacturing DNA. Creating DNA is crucial for R&D in numerous fields of synthetic biology which tackle essential societal issues: climate change thanks to the production of bioproduced materials, healthcare with new biotherapies - especially against cancer, or food security using better strains of plants. Synthesis is also an essential step towards of DNA data storage.

All these applications form the long-awaited synthetic biology revolution, and all rely on the capability to efficiently write life code to engineer biological systems. Current DNA synthesis methods are the major bottleneck. The enzymatic process developed by DNA Script, inspired by Nature, aims at improving both speed and efficiency by orders of magnitude. Avoiding the use of toxic reagents, this process will also contribute to a lower environmental footprint for this industry, as well as for its downstream applications.

DNA Script’s technological performances in the lab are 3 to 6 months away to overcome current offer. Project Rosalind will accelerate industrial scale-up of DNA Script’s production capability and performances. By developing extensive knowledge in DNA applications and structuring the company’s strategic and commercialization capabilities, Project Rosalind will also help DNA Script go commercial.

Enabling technologies such as DNA synthesis have tremendous impact on an ecosystem by accelerating R&D and industrialization cycles of its customer. The project will have a positive impact on the European biotech environment, and potentially trigger the emergence of European biotech leaders. Ultimately, through the numerous applications of synthetic DNA, it will benefit all European citizens.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ROSALIND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ROSALIND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More